Clinical Trials Logo

Leukemia, Chronic Myelogenous clinical trials

View clinical trials related to Leukemia, Chronic Myelogenous.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04795427 Active, not recruiting - Clinical trials for Leukemia, Chronic Myelogenous

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Start date: December 6, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this Chinese bridging study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of asciminib versus best available therapy in Chinese patients with Chronic Myelogenous Leukemia in chronic phase, previously treated with 2 or more tyrosine kinase inhibitors to support related indication registration in China. The primary objective of the study is to evaluate the Major Molecular Response (MMR) rate of asciminib treatment at 24 weeks.